Concerns Surrounding Shenzhen Weiguang Biological Products' (SZSE:002880) Performance
Concerns Surrounding Shenzhen Weiguang Biological Products' (SZSE:002880) Performance
Following the solid earnings report from Shenzhen Weiguang Biological Products Co., Ltd. (SZSE:002880), the market responded by bidding up the stock price. However, we think that shareholders should be cautious as we found some worrying factors underlying the profit.
繼深圳維光生物製品有限公司(SZSE:002880)發佈穩健的業績之後,市場的回應是提高了股價。但是,我們認爲股東應該謹慎行事,因爲我們發現了利潤背後的一些令人擔憂的因素。
View our latest analysis for Shenzhen Weiguang Biological Products
查看我們對深圳微光生物製品的最新分析
![earnings-and-revenue-history](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231103/0-cccc8533e4ff83b4699a5e603ffc15cf-0-c94db747fe05d15a5c42da6f9e8cdab5.png/big)
The Impact Of Unusual Items On Profit
不尋常物品對利潤的影響
To properly understand Shenzhen Weiguang Biological Products' profit results, we need to consider the CN¥21m gain attributed to unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And, after all, that's exactly what the accounting terminology implies. If Shenzhen Weiguang Biological Products doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.
爲了正確理解深圳維光生物製品的利潤業績,我們需要考慮歸因於不尋常物品的2100萬元人民幣的收益。我們不能否認,更高的利潤通常使我們感到樂觀,但如果利潤是可持續的,我們更願意這樣做。當我們計算數千家上市公司的數字時,我們發現,特定年份中不尋常的項目所帶來的提振通常不會在第二年重演。而且,畢竟,這正是會計術語的含義。如果深圳維光生物製品沒有看到這種貢獻重演,那麼在其他條件相同的情況下,我們預計其利潤將在本年度下降。
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
這可能會讓你想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看根據他們的估計描繪未來盈利能力的交互式圖表。
Our Take On Shenzhen Weiguang Biological Products' Profit Performance
我們對深圳維光生物製品盈利表現的看法
Arguably, Shenzhen Weiguang Biological Products' statutory earnings have been distorted by unusual items boosting profit. Because of this, we think that it may be that Shenzhen Weiguang Biological Products' statutory profits are better than its underlying earnings power. Nonetheless, it's still worth noting that its earnings per share have grown at 7.3% over the last three years. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. For example - Shenzhen Weiguang Biological Products has 1 warning sign we think you should be aware of.
可以說,深圳維光生物製品的法定收益因不尋常的項目而被扭曲了,從而提高了利潤。正因爲如此,我們認爲深圳維光生物製品的法定利潤可能優於其潛在的盈利能力。儘管如此,仍然值得注意的是,其每股收益在過去三年中增長了7.3%。本文的目的是評估我們可以多大程度地依靠法定收益來反映公司的潛力,但還有很多需要考慮的地方。考慮到這一點,除非我們對風險有透徹的了解,否則我們不會考慮投資股票。例如,深圳微光生物製品有 1 個警告標誌,我們認爲你應該注意。
This note has only looked at a single factor that sheds light on the nature of Shenzhen Weiguang Biological Products' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.
這份報告僅研究了揭示深圳維光生物製品利潤性質的單一因素。但是,如果你能夠將注意力集中在細節上,總會有更多值得發現的地方。有些人認爲高股本回報率是高質量業務的好兆頭。儘管可能需要代表你進行一些研究,但你可能會發現這份免費收集的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單很有用。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。